Study Shows MS Patients Receiving Stem Cell Treatment Still In Remission

Study Shows MS Patients Receiving Stem Cell Treatment Still In Remission

Overview A phase 2 study conducted, by Dr. Richard A. Nash, on 24 patients with relapsing-remitting MS showed extremely positive results, with 86% of patients relapse free for three years….

In Duchenne Muscular Dystrophy Stem Cells Found to be Faulty

In Duchenne Muscular Dystrophy Stem Cells Found to be Faulty

Overview In a new study by Stanford University Medical Center mice with a form of Duchenne Muscular Dystrophy (DMD)underwent progressive muscle degeneration and accumulated connective tissue as they aged. Now,…

Source Concord Acquires Beike Biotechnology Shares

Source Concord Acquires Beike Biotechnology Shares

On the evening of December 22, the Source Concord Cell Gene Engineering Co., Ltd. (Source Concord) announced a 13 percent (118.7 million yuan) acquisition of shares held by Dr. Xiang…

Altor BioScience and Shenzhen Beike Biotechnology Announce License Agreement for Immunotherapeutic ALT-803 in China

Altor BioScience and Shenzhen Beike Biotechnology Announce License Agreement for Immunotherapeutic ALT-803 in China

MIRAMAR, Fla. & SHENZHEN, China, Sep 10, 2014 (BUSINESS WIRE) — Altor BioScience Corporation (Altor), a U.S.-based developer of novel cancer immunotherapies, and Shenzhen Beike Biotechnology Co., Ltd. (Beike), a…

Ice Bucket Challenge Sweeps China

Ice Bucket Challenge Sweeps China

On a hot and sunny day in coastal Shenzhen, China, a small group of Beike Biotechnology’s international department was preparing to dump buckets of ice water on themselves. Why? More…

2014 Status Quo and Future Cell Therapy Technology Summit Grand Opening

2014 Status Quo and Future Cell Therapy Technology Summit Grand Opening

Taizhou City, Jiangsu Province, China August 8, 2014 / PRNewswire / – In recent years, with the rapid development of stem cell biology, immunology, molecular techniques, tissue engineering and other…


1 2 4 5 6 8 9